[en] Objective: To assess the structural and symptomatic efficacy of oral glucosamine sulfate and chondroitin sulfate in knee osteoarthritis through independent meta-analyses of their effects on joint space narrowing, Lequesne Index, Western Ontario MacMaster University Osteoarthritis Index (WOMAC), visual analog scale for pain, mobility, safety, and response to treatment. Methods: An exhaustive systematic research of randomized, placebo-controlled clinical trials published or performed between January 1980 and March 2002 that assessed the efficacy of oral glucosamine or chondroitin on gonarthrosis was performed using MEDLINE, PREMEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Current Contents, BIOSIS Previews, Health-STAR, EBM Reviews, manual review of the literature and congressional abstracts, and direct contact with the authors and manufacturers of glucosamine and chondroitin. Inclusion, quality scoring, and data abstraction were performed systematically by 2 independent reviewers who were blinded to sources and authors. Conservative approaches were used for clear assessment of potential efficacy. Results: Our results demonstrated a highly significant efficacy of glucosamine on all outcomes, including joint space narrowing and WOMAC. Chondroitin was found to be effective on Lequesne Index, visual analog scale pain, mobility, and responding status. Safety was excellent for both compounds. Conclusions: Our study demonstrates the structural efficacy of glucosamine and indistinguishable symptomatic efficacies for both compounds. Regarding the relatively sparse data on glucosamine and joint space narrowing and the absence of data on structural effects of chondroitin, further studies are needed to investigate the relationship among time, dose, patient baseline characteristics, and structural efficacy for an accurate, disease-modifying characterization of these 2 compounds.
Disciplines :
General & internal medicine
Author, co-author :
Richy, Florent
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Ethgen, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique : aspects spécifiques
Cucherat, M.
Henrotin, Yves ; Université de Liège - ULiège > Unité de recherche sur l'os et le cartillage (U.R.O.C.)
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis - A comprehensive meta-analysis
Publication date :
14 July 2003
Journal title :
Archives of Internal Medicine
ISSN :
0003-9926
eISSN :
1538-3679
Publisher :
Amer Medical Assoc, Chicago, United States - Illinois
Badia Llach X. Epidemiology and economic consequences of osteoarthritis. In: Reginster JY, Pelletier JP, Martel-Pelletier J, Henrotin Y, eds. Osteoarthritis: Clinical and Experimental Aspects. New York, NY: Springer; 1999:38-52.
Creamer P, Dieppe PA. Novel drug treatment strategies for osteoarthritis. J Rheumatol. 1993;20:1461-1464.
Carr AJ. Beyond disability: measuring the social and personal consequences of osteoarthritis. Osteoarthritis Cartilage. 1999;7:230-238.
Altman RD, Hochberg M, Moskowitz RW, Schnitzer J, on behalf of the American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis on the hip and the knee. Arthritis Rheum. 2000;43:1905-1915.
Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000;59:936-944.
Committee for Proprietary Medicinal Products. Points to Consider on Clinical Investigation of Medicinal Products Used in the Treatment of Osteoarthritis. London, England: European Agency for the Evaluation of Medicinal Products; July 1998.
Food and Drug Administration. Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis. Washington, DC: Food and Drug Administration; 1999. FDA document 07/1999.
Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the anti-inflammatory efficacy of chondroitin sulfate and diflonac sodium in patients with knee osteoarthritis. J Rheumatol. 1996;23:1385-1391.
Fioravanti A, Franci A, Anselmi F, Fattorini L, Marcolongo R. Clinical efficacy and tolerance of galactosoaminoglucuronoglycan sulfate in the treatment of osteoarthritis. Drugs Exp Clin Res. 1991;17:41-44.
Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998;6(suppl A):14-21.
Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozemberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3x 400 mg/day vs placebo. Osteoarthritis Cartilage. 1998;6(suppl A):25-30.
Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteaoarthritis (SYSDOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage. 1998;6(suppl A):31-36.
Conrozier T. Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&6). Presse Med. 1998;27:1862-1865.
Mazieres B, Loyau G, Menkes CJ, et al. Chondroitin sulfate for the treatment of coxarthrosis and gonarthrosis: a prospective, multicenter, placebo-controlled, double-blind trial with five months follow-up. Rev Rhum Mal Osteoartic. 1992;59:466-472.
Mazieres B, Combe B, Phan Van A, Tondut J, Grynfeltt M. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheumatol. 2001;28:173-181.
Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage. 1998;6(suppl A):39-46.
L'Hirondel JL. Klinische doppelblind-studie mit oral verabreichtem chondroitin-sulfat gegen placebo bei der tibiofemoralen gonarthrose (125 patienten). Litera Rheumatologica. 1992;14:77-85.
Pavelka K, Bucsi L, Manopulo R. Double-blind, dose effect study of oral CS 4&6 1200 mg, 800 mg, 200 mg, against placebo in the treatment of femorotibial osteoarthritis. Litera Rheumatologica. 1999;24:21-30.
Noack W, Fischer M, Förster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage. 1994;2:51-59.
Reichelt A, Förster KK, Fischer M, Rovati LC. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee: a randomized, placebo-controlled, double-blind study. Arzneimittelforschung. 1994;44:75-80.
Qiu GX, Gao SN, Giacovelli G, Rovati L, Setnikar I. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimittelforschung. 1998;48:469-474.
Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet. 2001;357:251-256.
Pujalte JM, Liavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthritis. Curr Med Res Opin. 1980;7:110-114.
Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate delays progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162:2113-2123.
Rovati LC. The clinical profile of glucosamine sulfate as a selective symptom modifying drug in osteoarthritis: current data and perspectives. Osteoarthritis Cartilage. 1997;5:72.
Rindone JP, Hiller D, Callacott E, Nordhaugen N, Arriola G. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med. 2000;172:91-94.
Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology. 2002;41:279-284.
Blotman F, Loyau G. Clinical trial with chondroitin sulfate in gonarthrosis. Osteoarthritis Cartilage. 1993;1(suppl):68.
Das AK Jr, Hammad T, Eifel J. Efficacy of a new class of agents (glucosamine and chondroitin sulfate) in the treatment of a osteoarthritis of the knee: a randomized double-blind placebo-controlled clinical trial. Paper presented at: American Academy of Orthopaedic Surgeons Annual Meeting; February 7, 1999; Anaheim, Calif. Paper 180.
Tzvetkova ES, Agababova ER, Mach ES, Bogomolova NA, Efficacy of chondroprotective agents during gonarthrosis. Osteoarthritis Cartilage. 1993;1(suppl): 68.
D'Ambrosio E, Casa B, Bompani R, Scali G, Scali M. Glucosamine sulphate: a controlled clinical investigation in arthrosis. Pharmatherapeutica. 1981;2:504-508.
Hehne HJ, Blasius K, Ernst HU. Treatment of gonarthritis with chondroprotective substances: a prospective comparative study of glucosamine sulphate and glycosaminoglycan polysulphate. Fortschr Med. 1984;102:676-682.
Lopes Vas A. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthritis of the knee in out-patients. Curr Med Res Opin. 1982;8:145-149.
Müller-Faßbender H, Bach GL, Haase W, Rovati L, Setnikar I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage. 1994;2:61-69.
Consoli G, Di Matteo L, Barlafante G, Agostinone A, Frattelli V. The analgesic effect of galactosaminoglycuronoglycan in the treatment of osteoarthrosis. Minerva Med. 1995;86:171-174.
Houpt JB, Mcmillan R, Paget-Dellio D, Russel A, Gahunia HK. Effects of glucosamine hydrochloride (GHcl) in the treatment of pain of osteoarthritis of the knee. J Rheumatol. 1999;26:2423-2430.
Leffler CT, Philippi AF, Leffler SG, Mosure JC, Kim PD. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med. 1999;164:85-91.
Drovanti A, Bignamini AA, Rovati LC. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo-controlled double-blind investigation. Clin Ther. 1980;3:260-272.
Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure modifying anti-osteoarthritis drug) in the treatment of finger joint osteoarthritis. Osteoarthritis Cartilage. 1998;6(suppl A):37-38.
Crolle G, D'Este E. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin. 1980;7:104-109.
Kerzberg EM, Roldan EJA, Castelli G, Huberman ED. Combination of glycosaminoglycans and acetylsalicylic acid in knee osteoarthritis. Scand J Rheumatol. 1987;16:377-380.
Rovetta G. Galactosaminoglycuronoglycan sulfate (matrix) in therapy of tibiofibular osteoarthritis of the knee. Drugs Exp Clin Res. 1991;17:53-57.
Vajaradul Y. Double-blind clinical evaluation of intra-articular glucosamine in outpatients with gonarthrosis. Clin Ther. 1981;3:336-343.
Tapadinhas MJ, Rivera IC, Bignamini AA. Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica. 1982;3:157-168.
Leeb BF, Schweitzer H, Montag K, Smolen J. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol. 2000;27:205-211.
McAlindon TE, Lavalley MP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000;283:1469-1475.
Lequesne L. The algofunctional indices for hip and knee osteoarthritis. J Rheumatol. 1997;24:779-781.
Lequesne L, Lery C, Samson M, Gerard DP. Indexes of severity for osteoarthritis of the hip and the knee. Scand J Rheumatol Suppl. 1987;65:85-89.
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833-1840.
Haynes RB, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC. Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J Am Med Inform Assoc. 1994;1:447-458.
Dickersin K, Scherer R, Lefebvre C. Identifying the relevant studies for systematic reviews. BMJ. 1994;309:1286-1291.
Jadad AR, Moore RA, Carroll D, Jenkinson C. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
Hunter JE, Schmidt FL. Methods of Meta-analysis: Correcting Error and Bias in Research Findings. Newbury Park, Calif: Sage Publications; 1990.
Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-129.
Cucherat M, Boissel JP, Leizorovicz A. Méta-analyse des Essais Thérapeutiques. Paris, France: Masson; 1997.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
Sterne JAC, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119-1129.
Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet. 1999;354:1896-1900.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
Buckland-Wright JC, Wolfe F, Ward RJ, Flowers N, Hayne C. Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy, of standing extended, semiflexed (MTP), and schuss view. J Rheumatol. 1999;26:2664-2674.
Mazzuca SA, Brandt KD, Buckwalter KA, Lane KA, Katz BP. Field test of the reproducibility of the semiflexed metatarsophalangeal view in repeated radiographic examinations of subjects with osteoarthritis of the knee. Arthritis Rheum. 2002;46:109-113.
